
Barbara Schneider, PhD, MBA
Barbara Schneider is Executive Director of Biostatistical Services at Advarra. She heads Advarra’s independent data monitoring committee and endpoint adjudication services, which provide trusted safety oversight for hundreds of clinical trials around the world. Prior to acquisition by Advarra in 2021, Schneider was the founder and CEO of Watermark Research Partners. Watermark was the first company to provide independent data safety monitoring board services and endpoint adjudication to the clinical trial industry.
Latest Posts by Barbara Schneider

The Importance of a Large Network of KOLs for DMCs
In the complex landscape of clinical trials, the data monitoring committee (DMC) serves as the...
Read More...
The Power of Worldwide Networks in Data and Safety Monitoring Boards
In an era where clinical trials are increasingly global, it’s more imperative than ever to...
Read More...
The Value of Continuity: Program-level Data Safety Monitoring Boards
In the realm of pharmaceutical development, ensuring the safety and efficacy of new treatments is...
Read More...
Understanding FDA’s 2024 Draft Guidance on DMCs
The FDA's 2024 draft guidance emphasizes the critical role of independent DMCs in clinical trials,...
Read More...